InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
59,479.20
(
0.41%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dakota

Send PM Follow Ignore
Followers 5
Posts 1266
Boards Moderated 0
Alias Born 09/03/2002

dakota

Re: Kag post# 4094

Monday, 06/05/2006 9:15:01 AM

Monday, June 05, 2006 9:15:01 AM

Post# of 30387
Kag you said "The logic would be that both cancer tumors and benign tumors produce new cells and thus both increase the amount of RECAF circulating in the blood and for that reason are more difficult to differentiate with a RECAF test."

BOCX said "The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells."

Please explain.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up